Monitoring vs early rituximab for ANCA reappearance in vasculitis
Treatments studied
Part of Brain & nervous system, Heart & circulation, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This study compares two ways of managing ANCA-associated vasculitis (inflammation of blood vessels) when ANCA antibodies reappear after remission. One approach is close monitoring with blood tests, and the other is giving rituximab infusions right away to prevent a flare-up. It aims to find out which strategy better prevents disease relapse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been diagnosed with either GPA or MPA (types of blood vessel inflammation).
- You must have been on a stable maintenance treatment with rituximab (Rituxan) for at least 18 months.
- You must be in complete remission (no active disease symptoms) at the start of the study.
- Your ANCA antibodies (a blood marker) must have become positive again in the last 3 months, even though you're in remission.
- You must not have had a serious infection recently, and you must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding avacopan, a medication that helps calm the immune system, to usual treatment can improve kidney function in people with a type of blood vessel inflammation called vasculitis that affects the kidneys. It's for people with severe kidney involvement who are starting standard treatment.
This study compares a new drug (avacopan) with lower doses of steroids to standard steroid treatment for people newly diagnosed with ANCA-associated vasculitis. The goal is to see if avacopan can control your disease with fewer steroid side effects.
This study tests a new combination treatment for people newly diagnosed with a type of kidney inflammation linked to ANCA-associated vasculitis. The treatment combines a targeted medication (obinutuzumab) with a low dose of steroids, aiming to control the disease with fewer side effects.
This trial studies whether extending low-dose prednisone alongside rituximab (given as infusions at set times) helps keep microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA) in remission. If you respond to initial treatment, the goal is to reduce the chance of relapse and maintain disease control.
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
This Phase 3 trial studies “salvage” treatment for people with active granulomatosis with polyangiitis (GPA) whose standard treatments have not worked well enough. It aims to improve disease control and reduce the need for ongoing higher-dose steroids.
Hear when a new Microscopic Polyangiitis (MPA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.